MX2021006194A - Inmunoterapias mediante el uso de celulas efectoras potenciadas derivadas de ipsc. - Google Patents

Inmunoterapias mediante el uso de celulas efectoras potenciadas derivadas de ipsc.

Info

Publication number
MX2021006194A
MX2021006194A MX2021006194A MX2021006194A MX2021006194A MX 2021006194 A MX2021006194 A MX 2021006194A MX 2021006194 A MX2021006194 A MX 2021006194A MX 2021006194 A MX2021006194 A MX 2021006194A MX 2021006194 A MX2021006194 A MX 2021006194A
Authority
MX
Mexico
Prior art keywords
effector cells
enhanced
immunotherapies
ipsc derived
derived effector
Prior art date
Application number
MX2021006194A
Other languages
English (en)
Inventor
Bahram Valamehr
Ryan Bjordahl
Tom Tong Lee
Original Assignee
Fate Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fate Therapeutics Inc filed Critical Fate Therapeutics Inc
Publication of MX2021006194A publication Critical patent/MX2021006194A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4613—Natural-killer cells [NK or NK-T]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)

Abstract

Se proporcionan métodos y composiciones para obtener células efectoras derivadas funcionalmente potenciadas obtenidas de la diferenciación dirigida de las iPSC modificadas genéticamente. Las células derivadas proporcionadas en la presente descripción tienen una edición del genoma estable y funcional que ofrece efectos terapéuticos potenciados o mejorados. También se proporcionan composiciones terapéuticas y el uso de estas que comprenden las células efectoras derivadas funcionalmente potenciadas solas, o con anticuerpos o inhibidores de punto de control en terapias combinadas.
MX2021006194A 2018-12-02 2019-11-25 Inmunoterapias mediante el uso de celulas efectoras potenciadas derivadas de ipsc. MX2021006194A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862774278P 2018-12-02 2018-12-02
PCT/US2019/063024 WO2020117526A1 (en) 2018-12-02 2019-11-25 IMMUNOTHERAPIES USING ENHANCED iPSC DERIVED EFFECTOR CELLS

Publications (1)

Publication Number Publication Date
MX2021006194A true MX2021006194A (es) 2021-06-30

Family

ID=70974390

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021006194A MX2021006194A (es) 2018-12-02 2019-11-25 Inmunoterapias mediante el uso de celulas efectoras potenciadas derivadas de ipsc.

Country Status (12)

Country Link
US (1) US20220127328A1 (es)
EP (1) EP3891177A4 (es)
JP (1) JP2022510207A (es)
KR (1) KR20210099601A (es)
CN (1) CN113166232A (es)
AU (1) AU2019392265A1 (es)
BR (1) BR112021010331A2 (es)
CA (1) CA3121128A1 (es)
IL (1) IL283607A (es)
MX (1) MX2021006194A (es)
SG (1) SG11202105480WA (es)
WO (1) WO2020117526A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114525255A (zh) * 2020-10-30 2022-05-24 未来智人再生医学研究院(广州)有限公司 一种表达il-11的多能干细胞衍生物及其应用
IL302476A (en) * 2020-11-04 2023-06-01 Fate Therapeutics Inc Induced pluripotent stem cells and immune effector cells for heterogeneous tumor control
US20230390337A1 (en) * 2020-11-04 2023-12-07 Fate Therapeutics, Inc. Engineered ipsc and persistent immune effector cells
EP4251741A1 (en) 2020-11-30 2023-10-04 CRISPR Therapeutics AG Gene-edited natural killer cells
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
EP4263600A1 (en) 2020-12-18 2023-10-25 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity
KR20230142470A (ko) * 2021-01-29 2023-10-11 알로젠 테라퓨틱스 인코포레이티드 동종이계 세포 산물의 T 세포 인식을 완화하기 위한TAP2, NLRC5, β2m, TRAC, RFX5, RFXAP, 및 RFXANK 중 하나 이상의 녹다운 또는 녹아웃
CN117615781A (zh) * 2021-02-25 2024-02-27 克莱格医学有限公司 Cd94工程化细胞及其组合物
AU2022255166A1 (en) * 2021-04-07 2023-09-28 Century Therapeutics, Inc. Compositions and methods for generating alpha-beta t cells from induced pluripotent stem cells
WO2022263682A1 (en) * 2021-06-18 2022-12-22 Onk Therapeutics Limited Double knockout natural killer cells
WO2023093763A1 (en) * 2021-11-24 2023-06-01 Hangzhou Qihan Biotechnology Co., Ltd. Systems and methods for cell-based immunotherapies cross-reference
EP4353741A1 (en) * 2022-10-14 2024-04-17 ONK Therapeutics Limited Double knockout natural killer cells

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9725764D0 (en) * 1997-12-04 1998-02-04 Isis Innovation HLA-E binding
ATE555383T1 (de) * 2006-06-22 2012-05-15 Novo Nordisk As Lösliche heterodimere rezeptoren und ihre verwendung
AU2017210031C1 (en) * 2016-01-20 2020-11-26 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies

Also Published As

Publication number Publication date
AU2019392265A1 (en) 2021-06-03
CN113166232A (zh) 2021-07-23
JP2022510207A (ja) 2022-01-26
EP3891177A1 (en) 2021-10-13
US20220127328A1 (en) 2022-04-28
WO2020117526A1 (en) 2020-06-11
BR112021010331A2 (pt) 2021-10-05
IL283607A (en) 2021-07-29
SG11202105480WA (en) 2021-06-29
CA3121128A1 (en) 2020-06-11
KR20210099601A (ko) 2021-08-12
EP3891177A4 (en) 2023-03-08

Similar Documents

Publication Publication Date Title
MX2020005477A (es) Inmunoterapias con el uso de células efectoras potenciadas derivadas de ipsc.
MX2020009896A (es) Celulas efectoras inmunitarias modificadas y usos de las mismas.
MX2020005701A (es) Células efectoras inmunitarias potenciadas y usos de las mismas.
MX2021006194A (es) Inmunoterapias mediante el uso de celulas efectoras potenciadas derivadas de ipsc.
MX2022000553A (es) Modificación de células efectoras inmunitarias y uso de las mismas.
MX2022003414A (es) Celulas efectoras con multiples objetivos y uso de las mismas.
MX2022006725A (es) Mejora de célula inmunitaria efectora derivada de ipsc mediante el uso de compuestos pequeños.
MX2021012054A (es) Reconstitución de cd3 en ipsc y células efectoras inmunitarias modificadas.
MX2022015863A (es) Combinación de tipos de células efectoras derivadas de células madre pluripotentes inducidas (ipsc) para uso en inmunoterapia.
MX2019011679A (es) Reemplazo de un pre-acondicionamiento citotoxico antes de una inmunoterapia celular.
MX2022004080A (es) Receptor de antígeno quimérico potenciado para la modificación de células efectoras inmunitarias y uso del mismo.
PH12021500004A1 (en) Pd-1/pd-l1 inhibitors
MX2020004043A (es) Composiciones y métodos para la edición génica de hemofilia a.
MX2023000731A (es) Composiciones utiles para enzimas de internalizacion.
MX2023005029A (es) Celula pluripotente inducida (ipsc) modificada geneticamente y celulas efectoras inmunitarias persistentes.
PH12018501656A1 (en) Methods for using fxr agonists
MX2023004326A (es) Células madre pluripotentes inducidas (ipsc) multiplexadas modificadas y células efectoras inmunitarias dirigidas a tumores sólidos.
SA517380984B1 (ar) طريقة لإنتاج خلايا سليفة في كبد بالغ
MX2020004541A (es) Edicion de genes de celulas primarias.
JOP20190146A1 (ar) تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
MX2017002900A (es) Terapia genica de globina para el tratamiento de hemoglobinopatias.
MX2019005402A (es) Terapias de combinacion del inhibidor de arginasa.
PH12019550027A1 (en) Uses of pd-1/pd-l1 inhibitors and/or ctla-4 inhibitors with a biologic containing multiple cytokine components to treat cancer
MX2018000897A (es) Celulas madre hematopoyeticas que expresan pd-l1 y usos.
MX2023004130A (es) Célula madre pluripotente inducida (ipsc) modificada y células efectoras inmunitarias activadas.